非剥脱1550nm铒玻璃点阵激光治疗活动性痤疮及痤疮瘢痕临床疗效观察

目的：观察非剥脱1550nm铒玻璃点阵激光治疗活动性痤疮及痤疮凹陷性瘢痕的临床疗效及安全性。方法：应用非剥脱性1550nm铒玻璃点阵激光治疗中重度痤疮患者25例，其中16例表现为活动性痤疮皮损（粉刺、丘疹、脓疱、结节）合并痤疮后凹陷性瘢痕，3例为痤疮瘢痕不伴活动性皮损，6例为活动性皮损不伴瘢痕形成。治疗1-3次，每次间隔3-4周，于末次治疗1个月后观察疗效。结果：活动性皮损22例，痊愈2例（9．1％）、显效14例（63．6％）、有效6例（27．3％）、无效或恶化0例（O％），总有效率为72．7％；痤疮凹陷性瘢痕19例，痊愈2例（10．5％）、显效10例（52．6％）、有效7例（36．8％）、无效或恶化0例（0％），总有效率为63．2％。且随着治疗次数的增加疗效逐步提高。术后仅出现轻度红肿，平均2-3天消退，均无色素沉着、水疱等不良反应，无1例恶化，患者满意率达840。结论：非剥脱1550nm铒玻璃点阵激光治疗活动性痤疮及痤疮后凹陷性瘢痕均有显著疗效，且安全、不艮反应轻，患者满意率高。     

Combination therapy using non‐ablative fractional laser and intralesional triamcinolone injection for hypertrophic scars and keloids treatment

Combinations of various treatment modalities were shown to be more effective than monotherapy when treating hypertrophic scars and keloids. This study was conducted to assess the effectiveness of combination therapy with non‐ablative fractional laser and intralesional steroid injection. From May 2015 to June 2017, a total of 38 patients with hypertrophic scars or keloids were evaluated. The control group of 21 patients received steroid injection alone, and 17 patients (the combined group) received 1550‐nm erbium‐glass fractional laser treatment and steroid injection simultaneously. The mean number of treatment sessions was statistically fewer in the combined group than in the control group (6.95 vs 5.47, P = .042). There was a significant difference in the patient's scale in the combined group (14.62 vs 22.82, P = .005); however, the observer's scale was not significantly different (17.92 vs 20.55, P = .549). The recurrence rate was 38.1% (8/21) in the control group and 35.3% (6/17) in the combined groups and showed no significant difference (P = .859). However, the mean remission period was statistically longer in the combined group (3.00 months vs 4.17 months, P = .042). Combination therapy with non‐ablative fractional laser and intralesional steroid injection showed better results for the treatment of hypertrophic scars and keloids with fewer treatment sessions, better patient satisfaction, and longer remission periods.